In a report issued on July 27, Ben Hendrix from RBC Capital maintained a Buy rating on Humana (HUM – Research Report), with a price target of $541.00. The company’s shares closed last Friday at $482.00, close to its 52-week high of $497.47.
According to TipRanks.com, Hendrix is a 1-star analyst with an average return of -2.2% and a 47.9% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Bright Health Group.
Humana has an analyst consensus of Strong Buy, with a price target consensus of $532.71, a 10.7% upside from current levels. In a report issued on July 14, Jefferies also maintained a Buy rating on the stock with a $560.00 price target.
The company has a one-year high of $497.47 and a one-year low of $351.20. Currently, Humana has an average volume of 839.9K.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HUM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Humana Inc. is a leading health insurance service provider in the United States. The company, through its Retail division, provides medicare benefits and state-based medicaid contracts, which are marketed on a retail basis to individuals. The Group and Specialty business offers employer group commercial fully-insured medical products and specialty health insurance benefits. Humana offers pharmacy solutions, provider services, home-based services, and clinical programs to the company’s health plan members as well as to third parties through the Healthcare Services segment.
Read More on HUM: